{"entity":{"id":"nct06974812","kind":"trial","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IBI3014 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06974812 by Innovent Biologics (Suzhou) Co. Ltd., with 250 participants planned, started 2025-04-18 and due to reach its primary completion in 2026-06-30. Interventions recorded: IBI3014.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06974812","url":"https://clinicaltrials.gov/study/NCT06974812"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06974812","phase":"1/2","setting":"A Phase 1/2 Study of IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrolled":250,"outcomes":[]},"route":"/trials/nct06974812/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}